STOCK TITAN
  1. Home
  2. Sec-filings
  3. ACAD
  4. [Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity

ACADIA (NASDAQ: ACAD) director granted RSUs and stock options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

ACADIA PHARMACEUTICALS director James M. Daly reported equity compensation activity on May 29, 2026. He exercised previously granted restricted stock units, receiving 8,107 shares of common stock, and held 12,148 common shares directly after these transactions.

On the same date, he was granted 9,311 restricted stock units, each representing one share of common stock, and 16,004 director stock options with an exercise price of $21.66 per share expiring on May 28, 2036. The options vest quarterly over one year, and the new restricted stock units are scheduled to vest in full on the earlier of one year after grant or the next annual meeting, with Daly electing to defer receipt of the underlying shares under the company’s 2024 Equity Incentive Plan.

Positive

  • None.

Negative

  • None.
Insider Daly James M
Role null
Type Security Shares Price Value
Exercise Restricted Stock Units 8,107 $0.00 --
Grant/Award Director Stock Options (Right to Buy) 16,004 $0.00 --
Grant/Award Restricted Stock Units 9,311 $0.00 --
Exercise Common Stock 8,107 $0.00 --
Holdings After Transaction: Restricted Stock Units — 0 shares (Direct, null); Director Stock Options (Right to Buy) — 16,004 shares (Direct, null); Common Stock — 12,148 shares (Direct, null)
Footnotes (1)
  1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
RSUs exercised into common stock 8,107 shares Restricted stock units converted to common stock on May 29, 2026
Common shares held after transactions 12,148 shares Direct ownership following May 29, 2026 transactions
New restricted stock units granted 9,311 units RSU grant on May 29, 2026, each for one common share
New director stock options granted 16,004 options Options on common stock granted May 29, 2026
Option exercise price $21.66 per share Exercise price for 16,004 director stock options
Option expiration date May 28, 2036 Expiration for director stock options granted May 29, 2026
Restricted Stock Units financial
"Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Director Stock Options financial
"Director Stock Options (Right to Buy) with an exercise price of 21.6600."
Stock options granted to a company’s board members that give those directors the right to buy company shares at a preset price after certain conditions are met. They matter to investors because they align directors’ incentives with shareholders—encouraging decisions that could raise the share price—but also create potential share dilution and future selling pressure once the options are exercised, similar to giving a delayed bonus tied to performance.
change in control financial
"and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended."
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
2024 Equity Incentive Plan financial
"as defined in the Issuer's 2024 Equity Incentive Plan, as amended."
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Daly James M
(Last)(First)(Middle)
C/O ACADIA PHARMACEUTICALS INC.
12830 EL CAMINO REAL, SUITE 400
(Street)
SAN DIEGO CALIFORNIA 92130
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
ACADIA PHARMACEUTICALS INC [ ACAD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock05/29/2026M8,107A(1)12,148D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)05/29/2026M8,107 (2) (2)Common Stock8,107$00D
Director Stock Options (Right to Buy)$21.6605/29/2026A16,004 (3)05/28/2036Common Stock16,004$016,004D
Restricted Stock Units(1)05/29/2026A9,311 (4) (4)Common Stock9,311$09,311D
Explanation of Responses:
1. Each restricted stock unit represents a contingent right to receive one share of Issuer's common stock.
2. The restricted stock units vested in full on May 29, 2026, the date on which an annual meeting of stockholders was held.
3. The shares subject to each stock option will vest quarterly over one year following the date of grant, with the final tranche vesting on the earlier of one year following the date of grant or the next annual meeting of stockholders.
4. The restricted stock units will vest in full on the earlier of one year following the date of grant or the next annual meeting of stockholders. The reporting person has elected to defer receipt of the shares of common stock underlying the restricted stock units until the earliest of the following: (i) the fifth anniversary of the date of grant of such restricted stock unit award; (ii) the date that is 30 days following the date on which the director ceases to serve as a member of the board of directors of the Issuer or otherwise provide services to the Issuer; and (iii) a change in control of the Issuer as defined in the Issuer's 2024 Equity Incentive Plan, as amended.
/s/ Jennifer J. Rhodes, Attorney-in-Fact06/01/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did ACAD director James M. Daly report?

James M. Daly reported equity compensation transactions, including the exercise of 8,107 restricted stock units into common shares and new grants of 9,311 restricted stock units and 16,004 director stock options on May 29, 2026.

How many ACADIA PHARMACEUTICALS (ACAD) shares does James M. Daly hold after this Form 4?

After these transactions, James M. Daly directly holds 12,148 shares of ACADIA PHARMACEUTICALS common stock. This figure reflects his position following the 8,107-share restricted stock unit exercise reported for May 29, 2026.

What equity awards were granted to James M. Daly by ACAD on May 29, 2026?

On May 29, 2026, James M. Daly received 9,311 restricted stock units and 16,004 director stock options. The options carry a $21.66 exercise price per share and vest quarterly over one year, while the restricted stock units vest in full on a specified future date.

What are the terms of James M. Daly’s new ACAD director stock options?

The new director stock options cover 16,004 shares of ACAD common stock at a $21.66 exercise price. They vest quarterly over one year from grant, with an expiration date of May 28, 2036, as disclosed in the Form 4 footnotes.

How do James M. Daly’s ACAD restricted stock units vest and settle?

The newly granted 9,311 restricted stock units vest in full on the earlier of one year after grant or the next annual stockholder meeting. Daly elected to defer receiving the underlying shares under terms described in ACADIA’s 2024 Equity Incentive Plan.